Consistent with IL-17A acting directly on keratinocytes to induce epidermal acanthosis in psoriasis as an effector cytokine (Ha et al, 2014), secukinumab was associated with faster and greater normalization of expression of transcripts dysregulated in psoriasis skin lesions at week 4. The gene discussed is IL17A; the disease is psoriasis.